Clear All
760 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
Momelotinib Ojjaara Multiple Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2023 In Use
NA Estradiol Estrace 0.5mg Hormonal Therapy Estrogen Yes 1998 In Use
NA Alpelisib Piqray 200mg Chemotherapy Enzyme Inhibitor PI3K Yes 2019 In Use
NA Altretamine Hexalen 50 mg Chemotherapy Alkylating Agent Triazines Yes 1990 2019 In Use
NA Alitretinoin Panretin 0.10% Hormonal Therapy Immunomodulator Retinoic Acid Derivative No 1999 In Use
J9057 Copanlisib Aliqopa 1mg Chemotherapy Enzyme Inhibitor PI3K No 2017 In Use
NA Abemaciclib Verzenio 200 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
Nirogacestat Ogsiveo 50mg, 100mg, 150mg Ancillary Therapy Miscellaneous Agent Ɣ Secretase Inhibitor Yes 2023 In Use
NA Vandetanib Caprelsa 300 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Yes 2011 In Use
NA Abemaciclib Verzenio 50 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Prednisolone Tebutate Hydeltra-TBA, Norpred TBA, Predalone T.B.A., Predate TBA, Predcor TBA, Prednisol TBA, Prednisolone TBA, TBA Pred 20 mg Hormonal Therapy Adrenal Glucocorticoid Corticosteroid No 1956 2003 In Use
NA Dasatinib Sprycel 50 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
NA Encorafenib Braftovi 50mg, 75mg Chemotherapy BRAF Inhibitor V600E Yes 2018 In Use
NA Naldemedine Symproic 0.2mg Ancillary Therapy Opioid Antagonist Yes 2018 In Use
NA Nilutamide Anadron, Nilandron 150 mg Hormonal Therapy Androgen Receptor Inhibitor Yes 1996 In Use
NA Erlotinib Tarceva 25 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
A9607 Lutetium Lu 177 vipivotide tetraxetan PLUVICTO 1 millicurie Radiopharmaceutical Radiopharmaceutical In Use
NA Erlotinib Tarceva 100 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
NA Aprepitant Emend 125 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
Asciminib Scemblix 20mg,40mg Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Yes 2021 In Use
NA Cabozantinib Cabometyx 40 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Imiquimod Aldara 5% Immunotherapy Immunomodulator Retinoic Acid Derivative No 1997 In Use
NA Tucatinib Tukysa 50mg,150mg Chemotherapy Tyrosine Kinase Inhibitor HER2 Yes 2020 In Use
NA Avapritinib Ayvakit 100mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA oxymetholone Anadrol-50 50 mg Ancillary Therapy Anabolic Steroid Androgen Yes 1972 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.